Trump announces 25% tariff on heavy truck imports

President Trump has announced new tariffs effective October 1, notably imposing a 100% duty on branded or patented pharmaceutical product imports, with exemptions for companies establishing U.S. manufacturing facilities. This measure, aimed at boosting domestic production and national security, has already prompted major pharma firms like Roche and Novartis to pledge billions in U.S. investments. Additional tariffs include 25% on heavy trucks, 50% on kitchen and bathroom fittings, and 30% on upholstered furniture, signaling a continued focus on reshoring and protecting U.S. industries.

Analysis

The U.S. administration has announced a significant escalation in trade policy, imposing a 100% tariff on imported branded and patented pharmaceutical products, effective October 1. This measure is explicitly designed to incentivize domestic manufacturing by offering exemptions to firms that are actively constructing or have broken ground on U.S. facilities. The policy targets a substantial market, with the U.S. having imported $212 billion in pharmaceutical goods in 2024. This tariff formalizes a trend that was already underway, as major foreign firms like Roche and Novartis have preemptively pledged $50 billion and $23 billion respectively in U.S. investments. Notably, U.S.-based majors Johnson & Johnson (JNJ) and Eli Lilly (LLY) were already observed shifting production back to the U.S., positioning them as potential direct beneficiaries. The positive sentiment scores (0.4) for both JNJ and LLY, in contrast to the mixed overall market sentiment (-0.1), underscore the market's perception that these firms hold a competitive advantage. This move is part of a broader protectionist agenda, which also includes new tariffs of 25% on heavy trucks, 50% on kitchen fittings, and 30% on furniture, signaling a sustained effort to reshore industrial supply chains across multiple sectors.

Key Decisions for Investors

• Investors should re-evaluate pharmaceutical portfolios to favor companies with substantial US manufacturing operations, such as Johnson & Johnson and Eli Lilly, which are positioned to gain a significant cost advantage over import-reliant competitors.
• Monitor non-U.S. pharmaceutical companies for announcements regarding new domestic manufacturing investments, as a credible commitment to building in the U.S. could mitigate the tariff impact and present a revised investment case.
• Given the broad tariff measures on trucks and consumer goods, it is prudent to review supply chain risks for companies in the automotive and home goods sectors, as they face new and immediate cost pressures.
• Closely watch for revised earnings guidance from companies highly dependent on pharmaceutical imports, as the 100% tariff represents a material margin risk for any firm without a clear path to exemption before the October 1 implementation date.